Transfection with miR-193b precursor and inhibitor were used to confirm targets of miR-193b. Proliferative effects of urokinase-type plasminogen activator (uPA) were determined by water-soluble ...

白细胞介素-6（Interleukin-6，IL-6）家族成员包括IL-6，抑瘤素M（oncostatin M，OSM），白血病抑制因子（Leukemia Inhibitory ...

The fibrin-specific plasminogen ... haemophilia A with inhibitors to Factor VIII that emerged from Roche's $4.8 billion takeover of Spark Therapeutics and was in a phase 1/2 dose-ranging trial.

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

Participants 1192 MI cases and 1506 population controls aged 45–70 years. Outcomes The levels of blood markers of inflammation (IL-6, TNF-α) and coagulation (fibrinogen, PAI-1) and MI risk. We ...

Over the past two decades, the role of vitreomacular adhesion in vitreomacular interface pathologies, such as vitreomacular traction syndrome, epiretinal membrane and macular hole, has been ...

Dean has Radio 1's Early Breakfast. Chappell Roan - exclusive Sound of 2025 interview Chappell Roan reflects on the last 12 months in an extensive chat with Jack Saunders. Your essential guide to ...

Introduction: To design effective small molecule inhibitors targeting the immune checkpoint PD-1/PD-L1 and to explore their inhibitory activity. Methods: In this paper, a total of 69 PD-1/PD-L1 ...